Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M14D1 in Advanced Small Cell Lung Cancer and Neuroendocrine Neoplasms
NCT07080242Phase 1Recruiting
- Sponsor
- SystImmune Inc.
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of BL-M14D1 in small cell lung cancer (SCLC), neuroendocrine carcinoma (NEC), prostate cancer (PCa) and 1 more, sponsored by SystImmune Inc. Primary endpoint: Safety and Tolerability of BL-M14D1 at 18 months. Started Apr 2025; status: recruiting.
02
Drugs
BL-M14D1
03
Conditions
small cell lung cancer (SCLC)neuroendocrine carcinoma (NEC)prostate cancer (PCa)Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT07080242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07080242.